Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: Disease control and preservation of organ function

Samant, Sandeep; Kumar, Parvesh; Wan, Jim Y.; Hanchett, Cathy; Vieira, Francisco; Murry, Tom; Wong, Frank S. H.; Robbins, K. Thomas

doi:10.1002/(sici)1097-0347(199910)21:7<595::aid-hed2>3.0.co;2-j

Cited by 100 publications

(62 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The standard treatment of advanced hypopharyngeal cancer is surgery and postoperative radiotherapy (Vandenbrouck et al 1977;Pingree et al 1987;Frank et al 1994;Axon et al 1997;Hoffman et al 1997;Eckel et al 2001), while chemoradiotherapy aimed at larynx-preservation has recently been reported (Kraus et al 1994;Clayman et al 1995;Lefebvre et al 1996;Zelefsky et al 1996;Samant et al 1999). Not all patients with hypopharyngeal cancer are treated by surgery for various reasons such as unresectable primary cancer or lymph node metastasis, patient refusal, and severe cardiopulmonary disorder (Eckel et al 2001).…”

Section: Discussionmentioning

confidence: 99%

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Tateda

Shiga

Yoshida

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The aim of this study is to evaluate the results of treatment for hypopharyngeal cancer and indicate the future prospect of the treatment. Seventy-four patients with squamous cell carcinoma of the hypopharynx admitted to Miyagi Cancer Center from 1993 through 2000 are reviewed. Sixty-four patients received radical treatment, and 10 patients received palliative treatment or no treatment. The cancer was advanced (stages III and IV) in 82% of all the patients. The overall 5-year survival rate of all the patients was 38%. The overall 5-year survival rate of 64 patients received radical treatment was 43%. The ten patients who received palliative treatment or no treatment died of cancer within 16 months. Fifty-two out of the 74 patients underwent neck dissection for the neck lymph node involvement; forty of the 52 patients underwent ipsilateral neck dissection and 12 underwent bilateral neck dissection. Four out of the 40 patients, who underwent ipsilateral neck dissection alone, developed late contralateral regional recurrence but were successfully treated by contralateral neck dissection at the time of recurrence. Twenty-three out of 74 patients had multiple primary cancers synchronously or metachronously (31%). Cause of the death of six patients out of 74 patients was confirmed to be primary cancers other than hypopharyngeal cancer, as judged by physicians in other department or other hospitals. Most of the patients died due to distant metastasis from hypopharyngeal cancer or other primary cancers. We therefore conclude that contralateral elective neck dissection which is frequently chosen for the treatment of hypopharyngeal cancer surgery is unnecessary. Even if locoregional control is accomplished, distant metastasis or multiple primary cancers emerge and make prognosis poor. To improve the prognosis, we should develop some strategy against hypopharyngeal cancer for each patient. New strategies including chemoprevention and surgery against distant metasistasis are necessary.hypopharyngeal cancer; distant metastasis; multiple primary cancers; elective neck dissection

show abstract

Section: Discussionmentioning

confidence: 99%

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Tateda

Shiga

Yoshida

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Cis-diamminedichloroplatinum(II) (cisplatin) is a chemotherapy drug used for several types of cancer: lung, testicular, ovary, neck, and head. [4][5][6] Cisplatin enters cells both by passive diffusion 7 and by active transporters.…”

Section: Introductionmentioning

confidence: 99%

Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt^I

et al. 2015

View full text Add to dashboard Cite

Pulse radiolysis measurements of the decay of hydrated electrons in solutions containing different concentrations of the oligonucleotide GTG with and without a cisplatin adduct show that the presence of a cisplatin moiety accelerates the reaction between hydrated electrons and the oligonucleotide. The rate constant of the reaction is found to be 2.23 × 10 10 mol −1 L s −1 , which indicates that it is diffusion controlled. In addition, we show for the first time the formation of a Pt I intermediate as a result of the reaction of hydrated electrons with GTG-cisplatin. A putative reaction mechanism is proposed, which may form the basis of the radiosensitization of cancer cells in concomitant chemoradiation therapy with cisplatin.

show abstract

“…[1][2][3][4] Radiosensitization by chemotherapeutic drugs is probably due to several factors including an increase in DNA damage, inhibition of DNA repair, diminution of the apoptosis threshold, and perturbation of the cell cycle such that cells remain in the sensitive phases for a longer time. 5 cis-Diamminedichloroplatinum(II) or cisplatin is a chemotherapeutic drug used in the treatment of ovary, testicular, lung, head, and neck cancers.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons

et al. 2014

View full text Add to dashboard Cite

The oligonucleotide TTTTTGTGTTT with or without a cisplatin adduct was reacted with hydrated electrons generated by ionizing radiation. Hydroxyl radicals were quenched with ethylenediaminetetraacetic acid (EDTA), and the solutions were bubbled with wet nitrogen to eliminate oxygen, a scavenger of hydrated electrons. Prior to irradiation, the structure of the initial cisplatin adduct was identified by mass spectrometry as G-cisplatin-G. Radiation damage to DNA bases was quantified by high-performance liquid chromatography (HPLC), after enzymatic digestion of the TTTTTGTGTTT-cisplatin complex to deoxyribonucleosides. The masses of the platinum adducts following digestion and separation by HPLC were measured by mass spectrometry. Our results demonstrate that hydrated electrons induce damage to thymines as well as detachment of the cisplatin moiety from both guanines in the oligonucleotide. This detachment regenerates both unmodified guanine and damaged guanine, in equimolar amounts. At 1000 Gy, a net average of 2.5 thymines and 1 guanine are damaged for each platinum lost from the oligonucleotide. Given the extensive base damage that occurs for each cisplatin adduct lost, it is clear that, prior to undergoing detachment, these adducts must catalyze several cycles of reactions of hydrated electrons with DNA bases. It is likely that a single reaction leads to the loss of the CIHR Author ManuscriptCIHR Author Manuscript CIHR Author Manuscript cisplatin adduct and the damage observed on the guanine base; however, the damage to the thymine bases must require the continued presence of the cisplatin adduct, acting as a catalyst. To our knowledge, this is the first time that platinum-DNA adducts have been shown to have catalytic activity. We propose two pathways for the interaction of hydrated electrons with TTTTTGTGTTTcisplatin: (1) the hydrated electron is initially captured by a thymine base and transferred by base to base electron hopping to the guanine site, where the cisplatin moiety detaches from the oligonucleotide via dissociative electron attachment, and (2) the hydrated electron interacts directly with the platinum-guanine adduct and induces detachment of the cisplatin moiety via dissociative electron attachment. Although the precise mechanism remains to be elucidated, our results provide important insights into the radiosensitization of DNA by cisplatin.

show abstract

Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: Disease control and preservation of organ function

Cited by 100 publications

References 9 publications

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt^I

Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons

Contact Info

Product

Resources

About

Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: Disease control and preservation of organ function

Cited by 100 publications

References 9 publications

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Management of the Patients with Hypopharyngeal Cancer: Eight-Year Experience of Miyagi Cancer Center in Japan

Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of PtI

Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons

Contact Info

Product

Resources

About

Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt^I